Australia's Firebrick Pharma jumps on U.S. patent for COVID nasal spray

Firebrick Pharma

17/02/2022 03:15

** Shares of pharmaceutical developer Firebrick  FRE.AX 
jump as much as 12.8% to A$0.530, set for their biggest pct
increase since Jan. 31 
    ** Co says its patent application covering the use of
Nasodine Nasal Spray in COVID-19 had been granted in the United
States  urn:newsml:reuters.com:*:nASX94FpzV
    ** "This patent covers the use of any povidone-iodine
formulation in the nose for reducing the viral load of
SARS-CoV-2"- FRE
    ** Shares hit their highest levels since Feb. 10 
    ** Stock down 11.3% as of last close, since its ASX-listing
on Jan. 28 

 (Reporting by Roushni Nair in Bengluru)
 ((Roushni.Nair@thomsonreuters.com;))